Fulcrum Therapeutics (FULC) Return on Capital Employed (2020 - 2025)
Historic Return on Capital Employed for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to 0.41%.
- Fulcrum Therapeutics' Return on Capital Employed fell 3000.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of 0.09% for FY2024, which is 4000.0% up from last year.
- Fulcrum Therapeutics' Return on Capital Employed amounted to 0.41% in Q3 2025, which was down 3000.0% from 0.05% recorded in Q2 2025.
- Fulcrum Therapeutics' Return on Capital Employed's 5-year high stood at 0.05% during Q2 2025, with a 5-year trough of 0.59% in Q2 2021.
- Its 5-year average for Return on Capital Employed is 0.38%, with a median of 0.43% in 2021.
- In the last 5 years, Fulcrum Therapeutics' Return on Capital Employed soared by 3500bps in 2024 and then tumbled by -3000bps in 2025.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Return on Capital Employed stood at 0.36% in 2021, then tumbled by -42bps to 0.51% in 2022, then rose by 15bps to 0.43% in 2023, then soared by 81bps to 0.08% in 2024, then crashed by -385bps to 0.41% in 2025.
- Its Return on Capital Employed was 0.41% in Q3 2025, compared to 0.05% in Q2 2025 and 0.08% in Q4 2024.